Tirzepatide vs Semaglutide vs the New Oral Pill
Released: Last reviewed:
Three FDA-approved GLP-1 options, three different trade-offs. Here is how injectable tirzepatide, semaglutide, and the new oral pill compare in 2026.
By Dr. Parmis, Lead Medical Researcher · Medically reviewed by Adam Kennah, M.D. · Last reviewed July 9, 2026 · Sources cited at the end.
Direct answer
As of 2026 there are three leading FDA-approved GLP-1 choices. For raw weight loss, injectable tirzepatide leads (~20% average; 20.2% vs semaglutide’s 13.7% head-to-head), semaglutide follows (~14–15%), and the new oral pill orforglipron (Foundayo) is lower (~11–12%) but needle-free and often cheapest with coverage. The best choice trades off results, convenience, cost, and tolerability — decide it with a clinician.
Weight loss compared
Side-by-side comparison
| Feature | Tirzepatide (Zepbound) | Semaglutide (Wegovy) | Orforglipron (Foundayo) |
|---|---|---|---|
| Form | Weekly injection | Weekly injection | Daily pill |
| Molecule | Dual GIP/GLP-1 | GLP-1 | GLP-1 (non-peptide) |
| Avg weight loss | ~20% | ~14–15% | ~11–12% |
| FDA approved | Yes | Yes | Yes (Apr 2026) |
| Needles | Yes | Yes | No |
| Advertised cost | Varies | Varies | $25 insured / $149 self-pay |
Sources: SURMOUNT-5 (NEJM), ATTAIN-1, Lilly/FDA. Costs change — verify directly.
How to choose
Prioritize maximum results? Injectable tirzepatide has the highest average. Want to avoid needles or keep monthly cost low with coverage? The oral pill is compelling. Already doing well on semaglutide? Strong results and familiarity may outweigh switching. Tolerability differs person to person, and cost depends heavily on insurance.
Where compounded tirzepatide fits
Compounded tirzepatide is not one of these FDA-approved options; it is a separate category that is not FDA-approved and now depends on patient-specific compounding with documented clinical need. With an approved pill now available, weigh that carefully. See our oral pill vs compounded and brand vs compounded guides, and the SURMOUNT-5 report.
Access and insurance in 2026
Real-world choice often comes down to coverage, not just efficacy. The oral pill’s advertised insured price is low, but eligibility depends on your plan; injectable brand pricing varies and manufacturer direct-pay programs have narrowed the gap with compounded routes. Because plans treat obesity, diabetes, and sleep apnea differently, the same person can face very different out-of-pocket costs depending on their diagnosis and which product is prescribed. Price all of your realistic options for your specific situation rather than assuming one is always cheapest.
Switching between GLP-1s
Switching is common and usually manageable, but it is not always a simple swap. Doses are not interchangeable across molecules, titration may restart, and side effects can reappear briefly as your body adjusts. People switch for tolerability, cost, coverage changes, or to pursue greater weight loss. Do it with a clinician who can map an appropriate starting dose and titration plan rather than transferring your old dose directly — and never combine two GLP-1 products at once.
Frequently asked questions
Which GLP-1 gives the most weight loss? In trials, injectable tirzepatide leads (about 20% average), semaglutide follows (about 14–15%), and the new oral pill orforglipron is lower (about 11–12%). Head-to-head, tirzepatide beat semaglutide 20.2% vs 13.7%.
Which is most convenient? The oral pill (Foundayo/orforglipron) needs no needles and can be taken any time. Tirzepatide and semaglutide are weekly injections.
Which is cheapest? It depends on coverage. The oral pill advertises $25/month insured or $149 self-pay via LillyDirect. Injectable brand pricing and compounded pricing vary — verify directly.
Is compounded tirzepatide one of these options? Compounded tirzepatide is not FDA-approved and is a separate category with narrower legal availability. The three compared here are FDA-approved medicines.
July 9, 2026: Published; figures verified against SURMOUNT-5 and ATTAIN-1 reporting.
Reviewed by Adam Kennah, M.D.
Sources
- SURMOUNT-5 (NEJM) — tirzepatide vs semaglutide head-to-head
- Eli Lilly — Foundayo (orforglipron) approval and pricing
- Drugs.com — orforglipron (Foundayo) ATTAIN-1 results
Important: Compounded tirzepatide is not FDA-approved and is not the same medicine as Mounjaro or Zepbound, the only FDA-approved tirzepatide products (Eli Lilly and Company). This page is educational and is not medical or legal advice. Weight-loss medications require evaluation and, when appropriate, a prescription from a licensed clinician. Individual results and side effects vary. Confirm current FDA status, pricing, and clinical guidance directly before acting.